The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells

Chem Commun (Camb). 2014 Jul 18;50(56):7427-30. doi: 10.1039/c4cc00419a.

Abstract

Asplatin, a fusion of aspirin and cisplatin, exhibits significant cytotoxicity in tumor cells and almost fully overcomes the drug resistance of cisplatin resistant cells. Asplatin is highly accumulated in cancer cells and is activated upon the reduction by ascorbic acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / chemistry*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / chemistry*
  • Aspirin / administration & dosage
  • Aspirin / chemistry*
  • Cell Line, Tumor
  • Cisplatin / administration & dosage
  • Cisplatin / chemistry*
  • Drug Combinations
  • Drug Synergism
  • Hep G2 Cells
  • Humans
  • MCF-7 Cells
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Tumor Burden / drug effects*
  • Xenograft Model Antitumor Assays / methods

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antineoplastic Agents
  • Drug Combinations
  • Cisplatin
  • Aspirin